This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Tuesday's Winners & Losers: Earnings Can't Boost Goldman

Goldman Sachs (GS - Get Report) on Tuesday posted a better-than-expected profit of $3.17 billion, or $7.01 a share, in the fiscal fourth quarter.

Still, Goldman shares closed in negative territory after a short-lived morning struggle to get above water. Shares finished at $201.61, down $7.02, or 3.36%.

Analysts polled by Thomson Financial were looking for $6.61 a share. Revenue sank 12.9% sequentially to $10.7 billion, but that still represents a 14.2% gain over last year and comes in ahead of the $10.2 billion average analyst estimate.

Elsewhere, New Jersey-based Asta Funding (ASFI - Get Report) slid 7.6% to $26.01 on a Kaufman Bros. downgrade to hold from buy.

Adobe (ADBE - Get Report) gained 2.6% a day after the company reported fourth-quarter results and offered guidance that topped Wall Street expectations.

Based on strong sales of its software package Creative Suite 3, the company said revenue rose 34% from a year ago to $911.2 million, beating analysts' expectations of $887.3 million. With earnings per share of 49 cents, Adobe estimates by a penny.

Analysts, however, remained mixed about the results. The stock was upgraded to a buy from hold by Deutsche Bank, while Kaufman Brothers downgraded it to hold from buy. Shares finished at $42.03, up $1.13, or 2.76%.

Robotics company iRobot (IRBT - Get Report), meanwhile, rose 4% after it announced a $286 million contract with the U.S. Army.

Under the contract, the Army could order up to 3,000 robots, spare parts, training and repair services over the next five years. iRobot will immediately deliver 101 robots for deployment. iRobot finsihed up 69 cents to $17.88.

Tuesday Morning (TUES - Get Report) shares plummeted 27% to $4.78 after the Dallas seller of home furnishings lowered guidance for its fiscal 2008 ending June 30. The company now expects sales to be between $943 million and $955 million and projects earnings per share of 58 cents to 65 cents. This falls short of the Street's mean 2008 forecast for EPS of 76 cents, per Thomson Financial.

Also crying for its mommy was BabyUniverse (KIDS). The Jupiter, Fla.-based operator of such Web sites as BabyUniverse.com, DreamtimeBaby.com and PoshTots.com got spanked with a 26% drop to $5.75 a share after reporting third-quarter earnings. The company posted a net loss of $5.6 million, or 31 cents a share, vs. a loss of $6 million, or 40 cents a share, in 2006. One analyst covering BabyUniverse expected a loss of 9 cents a share.

Epix Pharmaceuticals (EPIX) announced results from a midstage, two-week clinical trial of its drug candidate for Alzheimer's disease. The company said the drug was safe and well-tolerated and that patients who took the 150-mg dose showed statistically significant improvement in cognitive function and memory compared to placebo. Shares added 96 cents, or 35%, to $4.02.

Another winner, small-cap Escalon Medical (ESMC - Get Report), said Tuesday that its Drew Scientific subsidiary received approval from the Food and Drug Administration to market the D3 Hematology System, for automatic three-part differential blood analysis. Drew Scientific plans to begin shipments of the product in the U.S. before the end of the year. Shares rose $1.06, or 32%, to $4.34.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ADBE $77.63 -1.70%
ASFI $8.38 -0.24%
ESMC $1.64 6.98%
GS $189.67 -0.84%
IRBT $33.79 0.42%

Markets

DOW 18,096.90 -106.47 -0.58%
S&P 500 2,098.53 -9.25 -0.44%
NASDAQ 4,967.1410 -12.76 -0.26%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs